Sanofi Q3 revenue beats estimates on new launches; lifts outlook

Sanofi SA

30/10/2026 06:39

Overview
France pharma firm's Q3 revenue rose 14.3% at CER, beating analyst expectations
Business EPS for Q3 rose 19.6% at CER
Company upgraded FY 2026 guidance for sales and business EPS growth at CER

Outlook
Sanofi raises 2026 guidance, sees sales up by low-teens percentage at CER
Company expects 2026 business EPS to grow by a mid-teens percentage at CER
Sanofi says it is taking steps to offset Dupixent’s future loss of exclusivity

Result Drivers
NEW MEDICINES - Co said Q3 sales growth was driven by launches of ALTUVIIIO, Ayvakit, and Rezurock
DUPIXENT GROWTH - Co said strong Dupixent sales contributed to Q3 results
COST DISCIPLINE - Co attributed business EPS growth to cost discipline

Company press release: ID:nGNE9QLXll

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
EUR 14.44 bln
EUR 13.59 bln (10 Analysts)
Q3 EPS
 
EUR 2.52
 
Q3 Net Income
 
EUR 3.02 bln
 
Q3 Free Cash Flow
 
EUR 3.27 bln
 
Q3 Operating Income
 
EUR 5.43 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Sanofi SA is €93.00, about 22.1% above its October 29 closing price of €76.15
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
Oct 28 - Sanofi agrees to settle antitrust case in US over diabetes drug Lantus
Oct 27 - Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance
Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)